Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$49.70
-1.9%
$55.93
$22.59
▼
$68.73
$4.77B1.112.02 million shs1.19 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%+2.12%+2.12%-20.27%+46.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$49.70
-1.9%
$55.93
$22.59
▼
$68.73
$4.77B1.112.02 million shs1.19 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%+2.12%+2.12%-20.27%+46.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.69
Moderate Buy$72.5545.97% Upside

Current Analyst Ratings Breakdown

Latest TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/6/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Lower Price TargetOverweight$90.00 ➝ $86.00
11/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Lower Price TargetOutperform$78.00 ➝ $67.00
11/4/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$70.00 ➝ $72.00
11/4/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Lower Price TargetBuy$89.00 ➝ $78.00
10/20/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
DowngradeHold ➝ Strong Sell
9/24/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$75.00 ➝ $89.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Reiterated RatingOutperform$76.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Reiterated RatingBuy$67.00
9/18/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Reiterated RatingSell (E+)
8/17/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Reiterated RatingOverweight
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$651.03M7.33$0.36 per share139.87$1.28 per share38.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$1.29N/A16.46N/A-18.66%-185.69%-17.24%N/A

Latest TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.0555-$0.55-$0.4946-$0.55$195.29 million$224.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
26.72
3.00
2.95

Institutional Ownership

CompanyInstitutional Ownership
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
49795.99 million91.73 millionOptionable

Recent News About These Companies

Travere Therapeutics (TVTX) Stock Price Target 2026
What is HC Wainwright's Forecast for TVTX FY2026 Earnings?
Brokers Set Expectations for TVTX FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$49.70 -0.95 (-1.88%)
Closing price 04:00 PM Eastern
Extended Trading
$49.72 +0.02 (+0.04%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.